We don’t have a cure for COVID-19, and one isn’t on the immediate horizon. What we do have is a growing toolkit of treatments that can prevent severe illness and death, effective vaccines that reduce hospitalization, and a research pipeline working on better antivirals. But the nature of the virus itself makes a complete, once-and-for-all cure extremely unlikely. Here’s where things actually stand.
What “Curing” a Virus Actually Means
When most people ask about curing coronavirus, they’re imagining one of two things: a drug that eliminates the virus from your body once you’re sick, or a way to eradicate it entirely so no one gets infected again. Neither is realistic for SARS-CoV-2, and understanding why helps put the current progress in context.
Viruses are fundamentally different from bacteria. Antibiotics can kill bacteria directly, but antiviral drugs typically work by slowing viral replication enough for your immune system to finish the job. That’s why most antiviral treatments work best when taken early. Humanity has only fully eradicated one human virus in history: smallpox. That took decades, a globally coordinated vaccination campaign, and a virus that didn’t mutate rapidly or hide in animal populations. SARS-CoV-2 does both.
Where Treatments Stand Right Now
The closest thing we have to a “cure” is early antiviral treatment. Paxlovid remains the primary oral antiviral for people at high risk of severe COVID-19. It works by blocking a key enzyme the virus needs to copy itself, and it significantly reduces the risk of hospitalization and death when taken within the first five days of symptoms. It’s not a cure in the traditional sense. It doesn’t eliminate every trace of the virus. But for high-risk patients, it’s a genuine lifesaver.
New antivirals are in development. A drug called S-217622, developed by Shionogi in partnership with Hokkaido University, is in a Phase 3 global clinical trial. It targets the same enzyme as Paxlovid (called 3CL protease, which the virus needs to replicate) but has practical advantages: it’s taken once daily instead of twice, and it doesn’t require a second “booster” drug to maintain effective levels in the body. That simplicity matters, because Paxlovid interacts with a long list of common medications, which limits who can safely take it. If S-217622 proves effective, it would give doctors a more accessible option.
On the antibody front, researchers have identified a new class of broadly neutralizing antibodies that can still neutralize highly mutated variants, including JN.1 descendants. In lab studies published in Cell Reports, several of these antibodies retained activity against most or all variants tested, including Omicron subvariants. These aren’t available as treatments yet, but they represent a path toward antibody therapies that don’t become obsolete every time the virus mutates. Previous monoclonal antibody treatments lost effectiveness as Omicron and its descendants emerged, so durability is the key challenge here.
Why the Virus Is So Hard to Eliminate
SARS-CoV-2 mutates at a rate of roughly two nucleotide changes per month. That’s moderate compared to some viruses, but it’s enough to keep generating new variants that partially dodge immune protection from vaccines and prior infection. This process, called antigenic drift, is the same reason you need a new flu shot every year. The flu also undergoes more dramatic changes called antigenic shifts, where entirely new strains emerge that the population has almost no immunity against. SARS-CoV-2 hasn’t done that in the same way, but its steady accumulation of mutations in the spike protein keeps it a moving target.
There’s a second, more troubling challenge. Research published in The Lancet Infectious Diseases and other journals has documented that SARS-CoV-2 can persist in human tissues long after the initial infection clears. Viral RNA and proteins have been detected in the gut, the lining of the nasal passages, the brain, and even in platelets and their precursor cells in bone marrow. In some cases, immune activation and viral material persist for up to two years after infection. This tissue persistence is strongly linked to long COVID symptoms, and it complicates any future cure strategy. You can’t simply clear the virus from the bloodstream if it’s hiding in the gut lining or nervous system.
The virus also circulates in animal populations, meaning even if we could somehow eliminate it from every human on Earth, it could jump back from animals. This is the same reason we’ll never eradicate influenza.
Vaccines: Powerful but Not a Cure
Updated COVID vaccines continue to reduce severe illness, hospitalization, and death. But they don’t prevent infection entirely, and their effectiveness wanes over months as both your antibody levels decline and the virus evolves. This is why boosters are recommended, particularly for older adults and immunocompromised people.
The goal of next-generation vaccine research is a “pan-coronavirus” vaccine, one that would target parts of the virus that are shared across many coronaviruses and don’t mutate as quickly. If successful, this could provide longer-lasting and broader protection, potentially even against future coronavirus pandemics. Several candidates are in early-stage trials, but none are close to widespread availability.
What AI and New Technology Could Change
Artificial intelligence is accelerating drug discovery in ways that weren’t possible during the early pandemic. Machine learning tools can now screen millions of chemical compounds to find ones that might block the virus from attaching to human cells. Researchers have used this approach to identify compounds that bind to ACE2, the receptor SARS-CoV-2 uses to enter cells, potentially preventing infection at the earliest stage. These candidates are still in preclinical phases, far from pharmacy shelves, but the speed of identification has collapsed from years to months.
AI-driven protein design is also being used to create synthetic molecules that could act as decoys, binding to the virus before it reaches your cells. The technology is promising, but translating computational hits into safe, effective drugs still requires traditional clinical trials, which take years.
The Realistic Outlook
COVID-19 is settling into a pattern similar to influenza: a permanent respiratory virus that circulates seasonally, mutates regularly, and requires updated vaccines and treatments to manage. The scientific community is not close to eradicating it. What is improving, steadily, is how well we can treat it and how rarely it kills.
Hospitalization and death rates have dropped dramatically since 2020, driven by population-level immunity from both infection and vaccination, better clinical care, and available antivirals. For most healthy adults, a COVID infection in 2025 is a manageable illness. The remaining challenges are protecting vulnerable populations, developing treatments for long COVID, and building antivirals and vaccines that stay effective as the virus changes. Progress on all three fronts is real but incremental. The honest answer is that we’re not close to a cure, but we’re far closer to making the virus something most people can live with safely.